Based on the large number of studies assessing the impact of checkpoint inhibitors in cancer and the use of anti-PD1 antibodies as a cancer treatment, we selected a cancer model to conduct the initial assessments of the PD1 peptide antagonist efficacy in vivo. Here, PDCD1 is linked to cancer.